Mazdutide

玛仕度肽

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameMazdutide
Drug Alias Name信尔美OXM-3IBI-362LY-3305677
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucagon receptor
Therapy Area/IndicationsAlcoholismOverweightObesity +[11] 
Global Approved IndicationsOverweightObesity
Approved Indications in ChinaOverweightObesity
Original Approved Country/TerritoryMainland China
Original Approved Date2025/06/24
Country/TerritoryUnited StatesGermanyArgentina +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesEli Lilly And CompanyInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesInnovent Biologics(Hk)Ltd
Active IndicationsAlcoholismOverweightObesity +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG